|
|
|
|
|
|
|
|
|
|
|
|
|
09.12.25 - 14:06
|
Delphia Therapeutics Appoints Leading Cancer Expert Steve Kelsey, M.D., to Board of Directors (Business Wire)
|
|
|
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Delphia Therapeutics, Inc. (Delphia), a biopharmaceutical company pioneering an innovative new area of cancer biology – activation lethality – which targets cancer's surprising vulnerability to oncogene overactivation, today announced the appointment of Stephen (Steve) Kelsey, M.D., MB ChB, FRCP, FRCPath to its board of directors. Dr. Kelsey is a highly-accomplished physician-scientist, oncologist and cancer drug developer and currently serves as president, research & development at Revolution Medicines.
“Steve's deep expertise across oncology research, early clinical development and organizational leadership makes him an exceptional addition to our board,” said Kevin Marks, Ph.D., co-founder, president and CEO of Delphia. “His track record of advancing transformational cancer medicines—from first-in-human studies through approval—will be invaluable as Delphia advances its pipeline and evolves into a clinical-stage company. I look forward to working close...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
